CD36 in liver diseases

被引:0
|
作者
Liu, Yi [1 ]
Yin, Wenwei [1 ]
机构
[1] Chongqing Med Univ, Inst Viral Hepatitis, Dept Infect Dis, Key Lab Mol Biol Infect Dis,Minist Educ,Affiliate, Chongqing, Peoples R China
基金
中国国家自然科学基金;
关键词
CD36; liver cancer; liver fibrosis; NAFLD; NASH; CHAIN FATTY-ACIDS; UP-REGULATION; NONALCOHOLIC STEATOHEPATITIS; SCAVENGER RECEPTOR; HEPATIC STEATOSIS; EXPRESSION; FAT/CD36; INJURY; CELLS; DIET;
D O I
10.1097/HC9.0000000000000623
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cluster of differentiation 36 (CD36) is a transmembrane glycoprotein with the ability to bind to multiple ligands and perform diverse functions. Through the recognition of long-chain fatty acids, proteins containing thrombospondin structural homology repeat domains such as thrombospondin-1, and molecules with molecular structures consistent with danger- or pathogen-associated molecular patterns, CD36 participates in various physiological and pathological processes of the body. CD36 is widely expressed in various cell types, including hepatocytes and KCs in the liver, where it plays a pivotal role in lipid metabolism, inflammation, and oxidative stress. Accumulating evidence suggests that CD36 plays a complex role in the development of nonalcoholic simple fatty liver disease and NASH and contributes to the pathogenesis of inflammatory liver injury, hepatitis B/hepatitis C, liver fibrosis, and liver cancer. This review summarizes the current understanding of the structural properties, expression patterns, and functional mechanisms of CD36 in the context of liver pathophysiology. Furthermore, the potential of CD36 as a therapeutic target for the prevention and treatment of liver diseases is highlighted.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Frequency of CD36 deficiency in Thais analyzed by quantification of CD36 on cell surfaces and in plasma
    Phuangtham, Roongaroon
    Santoso, Sentot
    Leelayuwat, Chanvit
    Komvilaisak, Patcharee
    Ding, Haoqiang
    Romphruk, Amornrat V.
    TRANSFUSION, 2020, 60 (04) : 847 - 854
  • [12] Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice
    Devereux, Camille J.
    Bayliss, Jacqueline
    Keenan, Stacey N.
    Montgomery, Magdalene K.
    Watt, Matthew J.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2023, 324 (02): : E187 - E198
  • [13] Functional consequences of CD36 downregulation by TLR signals
    Zamora, Carlos
    Canto, Elisabet
    Nieto, Juan C.
    Angels Ortiz, M.
    Juarez, Candido
    Vidal, Silvia
    CYTOKINE, 2012, 60 (01) : 257 - 265
  • [14] The involvement of CD36 in monocyte activation by antiphospholipid antibodies
    Kato, M.
    Atsumi, T.
    Oku, K.
    Amengual, O.
    Nakagawa, H.
    Fujieda, Y.
    Otomo, K.
    Horita, T.
    Yasuda, S.
    Koike, T.
    LUPUS, 2013, 22 (08) : 761 - 771
  • [15] Associations of Plasma CD36 and Body Fat Distribution
    Wang, Yeli
    Koch, Manja
    di Giuseppe, Romina
    Evans, Kirsten
    Borggrefe, Jan
    Nothlings, Ute
    Handberg, Aase
    Jensen, Majken K.
    Lieb, Wolfgang
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (09) : 4016 - 4023
  • [16] Mapping of phosphatidylserine recognition region on CD36 ectodomain
    Banesh, Sooram
    Ramakrishnan, Vibin
    Trivedi, Vishal
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2018, 660 : 1 - 10
  • [17] Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma
    Kubo, Masahiko
    Gotoh, Kunihito
    Eguchi, Hidetoshi
    Kobayashi, Shogo
    Iwagami, Yoshifumi
    Tomimaru, Yoshito
    Akita, Hirofumi
    Asaoka, Tadafumi
    Noda, Takehiro
    Takeda, Yutaka
    Tanemura, Masahiro
    Mori, Masaki
    Doki, Yuichiro
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (02) : 610 - 619
  • [18] The origin of circulating CD36 in type 2 diabetes
    Alkhatatbeh, M. J.
    Enjeti, A. K.
    Acharya, S.
    Thorne, R. F.
    Lincz, L. F.
    NUTRITION & DIABETES, 2013, 3 : e59 - e59
  • [19] Humanized CD36 (hCD36) mouse model supports the preclinical evaluation of therapeutic candidates targeting CD36
    Xie, Xiulong
    Niu, Zhenlan
    Wang, Linlin
    Zhou, Xiaofei
    Yu, Xingyan
    Jing, Hongyan
    Yang, Yi
    EXPERIMENTAL ANIMALS, 2023, 72 (04) : 535 - 545
  • [20] CD36: Implications in cardiovascular disease
    Febbraio, Maria
    Silverstein, Roy L.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (11) : 2012 - 2030